awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q49180890-58022E45-2B6C-4DB1-8482-A4048D73FB68
Q49180890-58022E45-2B6C-4DB1-8482-A4048D73FB68
BestRank
Statement
http://www.wikidata.org/entity/statement/Q49180890-58022E45-2B6C-4DB1-8482-A4048D73FB68
Dipeptidyl peptidase-4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12-week, open label, randomized controlled study in Japan (PREFERENCE 4 study).
P2860
Q49180890-58022E45-2B6C-4DB1-8482-A4048D73FB68
BestRank
Statement
http://www.wikidata.org/entity/statement/Q49180890-58022E45-2B6C-4DB1-8482-A4048D73FB68
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
418123ad3dffb425fdcea308d09ddc3c9bdb6406
P2860
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.